Factor V R506Q mutation-Leiden: An independent risk factor for venous thrombosis but not coronary artery disease

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 2, 2001, Pages 111-116

  Irani Hakime, Noha ^a   Tamim, Hala ^a   Elias, Ghanem ^a   Choueiry, Salah ^a   Kreidy, Raghid ^a   Daccache, Jocelyn L ^a   Almawi, Wassim Y ^a  

^a SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

Author keywords

Coagulation; Epidemiology; Factor V Leiden; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; DNA;

ADULT; AGE; ALLELE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DNA DNA HYBRIDIZATION; DNA FLANKING REGION; ENZYME IMMUNOASSAY; FEMALE; GENDER; GENE EXPRESSION; GENE MUTATION; HETEROZYGOTE DETECTION; HUMAN; INCIDENCE; INHERITANCE; MAJOR CLINICAL STUDY; MALE; MUTANT; PATHOGENESIS; PERIPHERAL CIRCULATION; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; VEIN THROMBOSIS;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CHILD, PRESCHOOL; CORONARY DISEASE; FACTOR V; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LEBANON; MALE; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0034922928     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011268531377     Document Type: Article

References (40)

1. The mechanism of inactivation of human factor Va by activated protein C
2. Mutation in blood coagulation factor V associated with resistance to activated protein C
3. Characterization of the molecular defect in factor V R506Q
4. Resistance to activated protein C as risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management
5. Inherited predisposition to thrombosis
6. World distribution of factor V Leiden
7. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
8. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese
9. Absence of the factor V Leiden mutation in Ethiopians
10. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep venous thrombosis
11. APC-resistance and MnII genotype (Gln 506) of coagulation factor V are rare in Japanese population
12. Molecular risk factors for thrombosis
13. Activated protein C resistance - A major risk factor for thrombosis
14. Epidemiology of factor V Leiden: Clinical implications
15. Are we ready for factor V Leiden screening?
16. Molecular basis of protein S deficiency in three families also showing independent inheritance of factor V Leiden
17. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
18. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden
19. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease
20. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
21. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
22. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease
23. Coagulation factors II, V, VII, and X, prothrombin gene 20210G → A transition, and factor V Leiden in coronary artery disease
24. Resistance to activated protein C and the risk of premature myocardial infarction
25. Markers of thrombin and platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study
26. High prevalence of factor V mutation-Leiden in the eastern Mediterranean
27. The factor V R506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis
28. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis. A case-control study of 55 patients
29. 506 → Gln mutation in the gene for factor V (factor V Leiden)
30. The risk of recurrent deep venous thrombosis among heterzygous carriers of both factor V Leiden and the G20210A prothrombin mutation
31. The risk of recurrent venous thrombo-embolism in patients with and without factor V Leiden
32. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of anticoagulation
33. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease
34. The prothrombin 20210A allele and factor V Leiden are associated with venous thrombosis but not with early coronary artery disease
35. The prevalence of the prothrombin 20210 G → A mutation is not increased in angiographically confirmed coronary artery disease
36. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
37. Venous thrombosis: A multicausal disease
38. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses
39. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism
40. Factor V Leiden: Should all women be screened prior to commencing the contraceptive pill?